Array BioPharma Names Liam Ratcliffe, M.D., Ph.D., to Board of Directors
BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (ARRY) announced that it has elected Liam Ratcliffe, M.D., Ph.D., to its Board of Directors as an independent director. Dr. Ratcliffe has extensive background in drug development and translational medicine, including a 12-year tenure at Pfizer.
Liam Ratcliffe, M.D., Ph.D., Independent Director, Array BioPharma Board of Directors (Photo: Business Wire)
We are excited to announce Liams addition to the Array Board of Directors, said Kyle Lefkoff, Chairman of Array BioPharma. Liam brings to Array his world-class experience in the clinical development of our pain and inflammation portfolio.
Dr. Ratcliffe commented, This is an important time for Array and Im delighted to be part of the team. I look forward to working with Arrays new CEO, Ron Squarer, who brings his unique outlook and perspective.
Dr. Ratcliffe continued, Im honored to join the Array Board as an independent director, and I look forward to fulfilling a role in which I can reflect the broad interests of Arrays diverse shareholder base.
Dr. Ratcliffe is a General Partner at New Leaf Venture Partners and joined New Leaf in September 2008. Prior to joining New Leaf, Dr. Ratcliffe served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions at Pfizer included Vice President of Exploratory Development for the Mid West region, and Head of Experimental Medicine at Pfizer's Sandwich, UK Laboratories.
Dr. Ratcliffe received his M.D. and Ph.D. degrees in immunology from the University of Cape Town and his MBA degree from the University of Michigan. He completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and additional teaching hospitals in Cape Town, South Africa.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to www.arraybiopharma.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50256857&lang=en
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
Source: Array BioPharma Inc.Copyright Business Wire 2012